Post by icemandios on Mar 9, 2022 2:57:46 GMT
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
PR Newswire
MARLBOROUGH, Mass. , March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it is scheduled to present new preclinical data on PH-894, Phio's self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), in an in-person poster session at the AACR Annual Meeting 2022, which is being held in New Orleans, Louisiana , from April 8-13, 2022 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation Details are as follows:
Title: Local administration of BRD4-targeting self-delivering RNAi (PH-894) provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy
Author: Benjamin Cuiffo, et al.
Abstract Number: 4237
Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
The poster presentation will be accessible in person and virtually and will also be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it is scheduled to present new preclinical data on PH-894, Phio's self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), in an in-person poster session at the AACR Annual Meeting 2022, which is being held in New Orleans, Louisiana , from April 8-13, 2022 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation Details are as follows:
Title: Local administration of BRD4-targeting self-delivering RNAi (PH-894) provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy
Author: Benjamin Cuiffo, et al.
Abstract Number: 4237
Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
The poster presentation will be accessible in person and virtually and will also be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .